https://infobreast.it/letteratura/nuove-evidenze-sulla-via-della-de-escalation-nel-trattamento-adiuvante-del-tumore-mammario-her2-positivo-in-stadio-i/ 2020-02-07T09:59:35+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-609799244.jpg https://infobreast.it/il-caso-clinico/trattamento-di-prima-linea-per-carcinoma-mammario-metastatico-her2-positivo/ 2020-02-07T11:24:15+00:00 https://infobreast.it/wp-content/uploads/2020/01/cc-1-scaled.jpg https://infobreast.it/letteratura/quale-spazio-terapeutico-per-il-doppio-blocco-recettoriale-nella-terapia-adiuvante-del-tumore-mammario-her2-positivo/ 2020-02-10T10:43:23+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1178291704.jpg https://infobreast.it/letteratura/un-cavallo-di-troia-innovativo-nel-destino-del-tumore-mammario-her2-positivo/ 2020-02-10T10:46:23+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1182777455.jpg https://infobreast.it/letteratura/omettere-o-non-omettere-la-chirurgia-mammaria-nei-pazienti-con-risposta-clinica-e-radiologica-completa-dopo-terapia-neoadiuvante/ 2020-02-10T10:49:59+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-179781021.jpg https://infobreast.it/letteratura/her2climb-un-efficace-paradigma-di-studio-del-tumore-mammario-her2-positivo-nelle-popolazioni-sotto-rappresentate-negli-studi-clinici/ 2020-02-10T10:51:37+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1036106326.jpg https://infobreast.it/letteratura/le-fluoropirimidine-fanno-ancora-una-volta-la-differenza-nel-tumore-mammario-precoce/ 2020-02-10T10:54:11+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-931227330.jpg https://infobreast.it/letteratura/nuove-pillole-di-farmacologia-oncologica-il-paclitaxel-per-os-nel-tumore-mammario/ 2020-02-10T10:55:46+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-184134697.jpg https://infobreast.it/letteratura/nuove-evidenze-e-nuovi-dubbi-per-limmunoterapia-nel-tumore-mammario-triplo-negativo-in-stadio-precoce-cui-prodest/ 2020-02-10T10:58:16+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-174979938.jpg https://infobreast.it/letteratura/a-cosa-bisogna-porre-maggiormente-attenzione-nella-gestione-clinica-delle-donne-con-tumore-mammario-oltre-allandamento-della-malattia-oncologica/ 2020-02-10T11:02:15+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-157334849.jpg https://infobreast.it/letteratura/integratori-durante-la-chemioterapia-per-il-tumore-mammario-tu-quoque-brute/ 2020-02-10T11:03:04+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1045529268.jpg https://infobreast.it/il-punto-di-vista/highlights-dal-san-antonio-breast-cancer-symposium/ 2020-02-11T09:01:18+00:00 https://infobreast.it/wp-content/uploads/2020/01/ib-pdv1.jpg https://infobreast.it/letteratura/una-nuova-strategia-farmacologica-per-le-pazienti-con-tumore-mammario-her2-positivo-e-metastasi-encefaliche-in-progressione/ 2020-06-16T09:16:21+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-919347058.jpg https://infobreast.it/letteratura/la-sessualita-dopo-la-diagnosi-di-tumore-mammario-come-tenerne-conto-nella-scelta-della-terapia-ormonale-adiuvante/ 2020-06-16T09:16:28+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1023085380.jpg https://infobreast.it/letteratura/terapie-endocrine-a-confronto-per-il-trattamento-del-tumore-mammario-avanzato-positivo-al-recettore-degli-estrogeni-e-negativo-ad-her2-il-tete-a-tete-dello-studio-parsifal/ 2020-06-16T09:19:00+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1050760928.jpg https://infobreast.it/letteratura/mantenersi-attive-dopo-il-trattamento-del-tumore-mammmario-le-donne-francesi-ce-la-mettono-tutta/ 2020-06-16T09:20:16+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1222346423.jpg https://infobreast.it/il-caso-clinico/paziente-con-ricaduta-precoce-dopo-trattamento-adiuvante-e-neoadiuvante-per-carcinoma-mammario-her2/ 2020-06-16T10:04:27+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-858923684.jpg https://infobreast.it/il-centro/area-donna-breast-unit-asst-cremona/ 2020-06-16T10:38:34+00:00 https://infobreast.it/wp-content/uploads/2020/01/ic-2.jpg https://infobreast.it/letteratura/tumore-triplo-negativo-della-mammella-e-nuovi-segnali-di-beneficio-dellimmunoterapia-la-chiave-e-nella-selezione-dei-pazienti/ 2020-06-16T13:10:37+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1144368123.jpg https://infobreast.it/letteratura/inibitori-di-parp-nelle-donne-con-tumore-mammario-avanzato-e-portatrici-di-mutazione-germinale-dei-geni-brca-1-o-2-quali-novita-nei-trattamenti/ 2020-06-17T07:09:41+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1150499125.jpg https://infobreast.it/letteratura/le-basi-biologiche-del-tumore-mammario-her2-low-una-nuova-entita-biologica/ 2020-06-17T07:10:37+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1159234070.jpg https://infobreast.it/il-centro/azienda-ospedaliero-universitaria-maggiore-della-carita-di-novara/ 2020-06-22T08:20:19+00:00 https://infobreast.it/wp-content/uploads/2020/06/a-novara-ospedale-maggiore.jpg https://infobreast.it/il-punto-di-vista/update-nel-trattamento-del-carcinoma-mammario-her2-positivo-highlights-da-asco-2020/ 2020-06-23T13:05:34+00:00 https://infobreast.it/wp-content/uploads/2020/06/del-mastro.jpg https://infobreast.it/il-punto-di-vista/update-da-asco-ed-esmo-breast-cancer-virtual-meetings/ 2020-06-23T13:06:58+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1163101446.jpg https://infobreast.it/letteratura/un-anno-di-neratinib-dove-si-posizione-nel-trattamento-del-tumore-mammario-her2-positivo-nel-2020/ 2020-06-23T16:21:56+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-671767370.jpg https://infobreast.it/il-caso-clinico/terapia-adiuvante-estesa-nel-trattamento-del-carcinoma-mammario-her2-positivo/ 2020-10-21T13:34:09+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-477571467.jpg https://infobreast.it/letteratura/nessun-progresso-senza-conflitto-la-storia-dei-farmaci-cdk4-6-inibitori-nel-trattamento-adiuvante-del-tumore-mammario-e-appena-cominciata/ 2020-10-21T13:57:55+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-171259913.jpg https://infobreast.it/letteratura/trastuzumab-in-monoterapia-come-trattamento-adiuvante-per-il-tumore-mammario-her2-positivo-pazza-idea/ 2020-10-21T13:57:55+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-513387572.jpg https://infobreast.it/letteratura/tumore-della-mammella-cosa-cambia-per-le-pazienti-dopo-la-diagnosi-oncologica/ 2020-10-21T13:57:55+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-814531860.jpg https://infobreast.it/letteratura/lo-sviluppo-delle-piccole-molecole-per-il-trattamento-del-tumore-mammario-her2-e-in-continua-evoluzione-recenti-novita-nella-malattia-metastatica/ 2020-10-21T14:32:31+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1093297920.jpg https://infobreast.it/il-centro/breast-unit-irccs-policlinico-s-orsola-malpighi-azienda-ospedaliero-universitaria-di-bologna/ 2020-10-21T14:42:12+00:00 https://infobreast.it/wp-content/uploads/2020/10/santorsola.jpg https://infobreast.it/il-punto-di-vista/carcinoma-mammario-her2-positivo-obiettivo-personalizzazione-del-trattamento/ 2020-10-21T14:44:13+00:00 https://infobreast.it/wp-content/uploads/2020/10/p-marchetti.jpg https://infobreast.it/letteratura/t-dm1-per-il-trattamento-del-tumore-mammario-her2-positivo-con-metastasi-encefaliche-nuove-evidenze-rimettono-la-molecola-in-gioco/ 2020-10-21T15:10:52+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1226583757.jpg https://infobreast.it/letteratura/tinture-permanenti-per-capelli-quale-rischio-per-il-tumore-della-mammella-uno-studio-recentissimo-sembra-mettere-in-chiaro-la-questione/ 2020-10-21T15:11:37+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-962517528.jpg https://infobreast.it/letteratura/lautosomministrazione-di-farmaci-biologici-a-casa-ancora-unutopia-in-oncologia-un-recente-studio-con-il-trastuzumab-potrebbe-cambiare-il-paradigma-di-healthcare-delivery/ 2020-10-21T15:12:10+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1036354910.jpg https://infobreast.it/il-caso-clinico/impatto-dei-trattamenti-anti-her2-nel-controllo-a-lungo-termine-della-malattia-metastatica/ 2020-12-22T13:14:32+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-801948192.jpg https://infobreast.it/letteratura/screening-mammografico-per-la-diagnosi-precoce-del-tumore-mammario-quanto-serve-e-perche-e-imperativo-ripartire/ 2020-12-22T13:31:27+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-623615910.jpg https://infobreast.it/letteratura/la-partecipazione-dei-pazienti-agli-studi-clinici-oncologici-e-una-questione-di-volere-o-potere/ 2020-12-22T13:32:47+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-1036106326.jpg https://infobreast.it/letteratura/nella-scelta-della-terapia-adiuvante-per-le-pazienti-con-tumore-mammario-endocrino-responsivo-vince-lapproccio-costruito-intorno-al-paziente/ 2020-12-22T13:34:51+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-840201300.jpg https://infobreast.it/letteratura/che-ne-facciamo-degli-inibitori-delle-chinasi-ciclina-dipendente-4-e-6-nel-setting-adiuvante-del-tumore-mammario-ora-nuovi-dati-a-complicare-i-fatti/ 2020-12-22T13:36:45+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-179310850.jpg https://infobreast.it/letteratura/a-che-punto-siamo-con-le-strategie-di-prevenzione-e-controllo-del-tumore-mammario-nei-piani-nazionali-di-oncologia/ 2020-12-22T13:39:47+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-495266744.jpg https://infobreast.it/letteratura/strategie-di-mantenimento-con-un-regime-terapeutico-de-intensificato-nella-prima-linea-metastatica-per-le-pazienti-con-tumore-mammario-le-nuove-evidenze-dalloriente/ 2020-12-22T13:42:20+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-842432852.jpg https://infobreast.it/letteratura/comorbilita-psichiatriche-nelle-donne-con-una-diagnosi-di-tumore-della-mammella-come-cambia-la-gestione-oncologica/ 2020-12-22T13:44:27+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-1181043348.jpg https://infobreast.it/letteratura/le-ultime-news-sul-neratinib-dal-san-antonio-breast-cancer-symposium-2020-come-cambia-la-pratica-clinica/ 2020-12-23T08:08:02+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-157502604.jpg https://infobreast.it/il-punto-di-vista/sabcs-2020-update-nel-trattamento-adiuvante-del-carcinoma-mammario-her2/ 2020-12-23T09:53:38+00:00 https://infobreast.it/wp-content/uploads/2020/12/DiCosimoYT.jpg https://infobreast.it/il-centro/azienda-ospedaliera-papardo-messina/ 2021-02-10T14:58:48+00:00 https://infobreast.it/wp-content/uploads/2020/12/papardo.jpg https://infobreast.it/il-punto-di-vista/conferme-per-neratinib-in-adiuvante-nel-carcinoma-mammario-her2-positivo/ 2021-03-29T08:50:33+00:00 https://infobreast.it/wp-content/uploads/2020/06/de-laurentiis.jpg https://infobreast.it/il-caso-clinico/stretegia-terapeutica-in-un-caso-di-carcinoma-mammario-her2-con-localizzazioni-encefaliche/ 2021-03-29T14:47:36+00:00 https://infobreast.it/wp-content/uploads/2021/03/ib_cc.jpg https://infobreast.it/il-punto-di-vista/st-gallen-ibc-conference-take-home-messages/ 2021-03-29T14:53:49+00:00 https://infobreast.it/wp-content/uploads/2021/03/cazzaniga.jpg https://infobreast.it/letteratura/antracicline-o-sali-di-platino-nel-trattamento-neoadiuvante-del-carcinoma-mammario-triplo-negativo/ 2021-03-29T15:21:53+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1036106326.jpg https://infobreast.it/letteratura/novita-in-tema-di-terapia-endocrina-adiuvante-negli-uomini-con-tumore-della-mammella-inibitori-delle-aromatasi-si-o-no/ 2021-03-29T15:21:53+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1145877451.jpg https://infobreast.it/letteratura/screening-del-tumore-al-seno-nelle-persone-transgender-chi-quando-e-come/ 2021-03-29T15:21:53+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1253914240.jpg https://infobreast.it/letteratura/vaccino-per-il-covid19-nelle-donne-con-tumore-mammario-avanti-in-sicurezza/ 2021-03-30T08:04:36+00:00 https://infobreast.it/wp-content/uploads/2021/03/vaccino-COVID.jpg https://infobreast.it/letteratura/tumore-della-mammella-er-low-positive-una-nuova-entita-oppure-un-revival/ 2021-03-30T08:06:52+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-671767370.jpg https://infobreast.it/letteratura/neratinib-nuovi-dati-consolidano-ulteriormente-il-ruolo-nella-malattia-her2-positiva/ 2021-03-30T08:07:49+00:00 https://infobreast.it/wp-content/uploads/2021/03/dati.jpg https://infobreast.it/letteratura/nuovi-dati-sulle-signature-genomiche-nelle-donne-premenopausali-con-tumore-mammario-operato-e-ancora-una-questione-di-interpretazione/ 2021-03-30T08:09:42+00:00 https://infobreast.it/wp-content/uploads/2021/03/genomica.jpg https://infobreast.it/il-centro/breast-unit-ospedale-ramazzini-di-carpi/ 2021-03-30T08:12:59+00:00 https://infobreast.it/wp-content/uploads/2021/03/ospedale-ramazzini.jpg https://infobreast.it/letteratura/cardiotossicita-e-nuove-immunoterapie-adiuvanti-per-il-tumore-mammario-quale-sicurezza/ 2021-06-25T12:35:06+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-919347058.jpg https://infobreast.it/letteratura/un-prezioso-focus-sul-tumore-lobulare-della-mammella-evidenze-dallo-studio-gelato/ 2021-06-25T12:35:06+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1050760928.jpg https://infobreast.it/letteratura/un-farmaco-target-per-il-trattamento-adiuvante-in-pazienti-con-mutazione-germinale-di-brca/ 2021-06-25T12:35:06+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-931227330.jpg https://infobreast.it/letteratura/tempistiche-nel-definire-il-priority-setting-gli-screening-oncologici-non-vanno-messi-in-secondo-piano/ 2021-06-25T12:35:06+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-157334849.jpg https://infobreast.it/letteratura/la-saga-della-capecitabina-post-neoadiuvante-nel-tumore-triplo-negativo/ 2021-06-25T12:35:33+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-179781021.jpg https://infobreast.it/il-punto-di-vista/stratificazione-del-rischio-e-durata-del-trattamento-nuove-evidenze/ 2021-06-25T13:57:48+00:00 https://infobreast.it/wp-content/uploads/2021/06/LeonardiYT.jpg https://infobreast.it/letteratura/un-nuovo-tentativo-di-de-escalation-della-terapia-adiuvante-nelle-pazienti-con-tumore-mammario-her2-positivo/ 2021-06-25T13:59:14+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-184134697.jpg https://infobreast.it/letteratura/medicina-integrativa-complementare-e-alternativa-facciamo-chiarezza/ 2021-06-25T14:01:35+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1144368123.jpg https://infobreast.it/letteratura/il-trattamento-adiuvante-esteso-con-neratinib-nel-tumore-her2-positivo-quanto-e-importante-completare-un-anno-di-terapia/ 2021-06-25T14:08:00+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-671767370.jpg https://infobreast.it/il-centro/aorn-antonio-cardarelli-napoli/ 2021-06-25T14:18:53+00:00 https://infobreast.it/wp-content/uploads/2021/06/ospedale-cardarelli.jpg https://infobreast.it/il-punto-di-vista/early-breast-cancer-highlights-da-asco-2021/ 2021-06-25T14:21:34+00:00 https://infobreast.it/wp-content/uploads/2021/06/infoBreast-conte.jpg https://infobreast.it/il-caso-clinico/tossicita-cardiologica-in-corso-di-trattamento-adiuvante-anti-her2-in-un-caso-di-paziente-con-carcinoma-mammario/ 2021-09-06T10:02:54+00:00 https://infobreast.it/wp-content/uploads/2021/06/iStock-1197977144.jpg https://infobreast.it/letteratura/prevenzione-del-tumore-mammario-nelle-donne-con-comorbilita-psichiatrica-attenzione-ai-farmaci-neurolettici/ 2021-10-14T07:34:42+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1226583757.jpg https://infobreast.it/letteratura/neratinib-nuovi-insight-per-luso-adiuvante-nel-setting-ad-alto-rischio/ 2021-10-14T07:39:25+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-623615910.jpg https://infobreast.it/letteratura/farmaci-oncologici-per-il-tumore-mammario-interazioni-con-la-dieta/ 2021-10-14T07:40:52+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1182847134-scaled.jpg https://infobreast.it/letteratura/eventi-coronarici-acuti-in-pazienti-con-tumore-mammario-metastatico-quale-approccio/ 2021-10-14T07:41:33+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1253914240.jpg https://infobreast.it/letteratura/carboplatino-neoadiuvante-nel-tumore-triplo-negativo-della-mammella-nuove-considerazioni/ 2021-10-14T07:47:47+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-842432852.jpg https://infobreast.it/letteratura/de-escalation-del-trattamento-adiuvante-per-le-pazienti-con-tumore-mammario-her2-back-from-esmo21/ 2021-10-14T07:49:08+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-1199586270.jpg https://infobreast.it/letteratura/tumori-lobulari-della-mammella-ruolo-della-chemioterapia-adiuvante/ 2021-10-14T07:49:41+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1050760928.jpg https://infobreast.it/letteratura/nuove-evidenze-su-covid19-e-cancro-cosa-sappiamo/ 2021-10-14T07:50:27+00:00 https://infobreast.it/wp-content/uploads/2021/03/vaccino-COVID.jpg https://infobreast.it/il-punto-di-vista/terapia-adiuvante-estesa-nel-setting-ad-alto-rischio-update-da-esmo-2021/ 2021-10-14T13:28:22+00:00 https://infobreast.it/wp-content/uploads/2021/10/FabiYT.jpg https://infobreast.it/il-podcast/ruolo-del-trattamento-neoadiuvante-nel-carcinoma-della-mammella/ 2021-10-14T13:48:24+00:00 https://infobreast.it/wp-content/uploads/2021/10/ib_pod-1021.jpg https://infobreast.it/il-centro/azienda-ospedaliera-universitaria-pisana/ 2021-10-14T13:49:17+00:00 https://infobreast.it/wp-content/uploads/2021/10/AO-Pisana.jpg https://infobreast.it/il-caso-clinico/fattori-predisponenti-alla-recidiva-dopo-risposta-patologica-completa/ 2021-10-14T14:13:43+00:00 https://infobreast.it/wp-content/uploads/2021/10/ib_cc-1021.jpg https://infobreast.it/letteratura/covid19-e-tumore-mammario-che-succedera/ 2021-12-22T11:37:06+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1045529268.jpg https://infobreast.it/letteratura/antracicline-nella-terapia-adiuvante-del-tumore-mammario-her2-negativo/ 2021-12-22T11:39:31+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1169740281.jpg https://infobreast.it/letteratura/emerald-e-tempo-di-riconsiderare-il-disegno-degli-studi-di-fase-3/ 2021-12-22T11:46:21+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-840201300.jpg https://infobreast.it/letteratura/programmi-di-prevenzione-del-cancro-mammario-linvestment-case-delloms/ 2021-12-22T11:50:08+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-1199586270.jpg https://infobreast.it/letteratura/prendersi-cura-delle-donne-con-tumore-mammario-in-stadio-1-3-una-questione-di-cuore/ 2021-12-22T11:50:52+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-671767370.jpg https://infobreast.it/letteratura/resistenza-ai-farmaci-anti-her2-nel-tumore-mammario-il-caso-mapk/ 2021-12-22T11:53:07+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1226583757.jpg https://infobreast.it/letteratura/profiling-molecolare-nel-tumore-metastatico-il-safir02-breast/ 2021-12-22T11:56:49+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-179310850.jpg https://infobreast.it/letteratura/dallo-studio-eleanor-evidenze-di-real-life/ 2021-12-22T12:03:36+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1050760928.jpg https://infobreast.it/il-punto-di-vista/potenziamento-e-depotenziamento-terapeutico-nel-carcinoma-mammario-her2-il-punto-da-sabcs-2021/ 2021-12-23T10:23:25+00:00 https://infobreast.it/wp-content/uploads/2021/12/pdv-1221.jpg https://infobreast.it/il-podcast/carcinoma-mammario-her2-positivo-ad-alto-rischio-approccio-terapeutico/ 2021-12-23T10:33:12+00:00 https://infobreast.it/wp-content/uploads/2021/12/ip-1221.jpg https://infobreast.it/il-caso-clinico/gestione-delle-tossicita-nel-trattamento-adiuvante/ 2021-12-23T11:56:26+00:00 https://infobreast.it/wp-content/uploads/2021/12/cc-1221.jpg https://infobreast.it/letteratura/updated-overall-survival-results-from-the-first-line-population-in-the-phase-iii-monaleesa-3-trial-of-postmenopausal-patients-pts-with-hr-her2-advanced-breast-cancer-treated-with-ribociclib-fulv/ 2022-05-23T08:34:50+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1169740281.jpg https://infobreast.it/letteratura/development-of-a-prognostic-gene-expression-signature-for-early-stage-her2-positive-breast-cancer-patients/ 2022-05-23T08:39:21+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-477571467.jpg https://infobreast.it/letteratura/biobanking-in-breast-cancer-10-years-of-practice-at-the-european-institute-of-oncology/ 2022-05-23T08:40:04+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-1150499125.jpg https://infobreast.it/letteratura/exploratory-biomarker-analysis-from-neoadjuvant-atezolizumab-pertuzumab-trastuzumab-plus-docetaxel-neo-path-in-her2-early-breast-cancer/ 2022-05-23T08:43:10+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1036106326.jpg https://infobreast.it/letteratura/optimal-18f-fdg-pet-ct-cut-off-for-pathological-complete-response-prediction-in-her2-positive-early-breast-cancer-patients-treated-with-neoadjuvant-trastuzumab-and-pertuzumab-in-phergain-trial/ 2022-05-23T08:44:25+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1145877451.jpg https://infobreast.it/letteratura/effect-of-diarrheal-prophylaxis-or-dose-escalation-on-neratinib-associated-diarrhea-and-tolerability-in-patients-with-her2-early-stage-breast-cancer-final-findings-from-the-control-trial/ 2022-05-23T08:49:44+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1226583757.jpg https://infobreast.it/letteratura/health-related-quality-of-life-with-pembrolizumab-chemotherapy-vs-placebo-chemo-as-1l-treatment-for-advanced-triple-negative-breast-cancer-results-from-keynote-355/ 2022-05-23T08:50:32+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1182847134-scaled.jpg https://infobreast.it/letteratura/patient-reported-outcomes-from-destiny-breast03-a-randomized-phase-3-study-of-trastuzumab-deruxtecan-vs-trastuzumab-emtansine-in-patients-with-her2-positive-metastatic-breast-cancer/ 2022-05-23T08:52:32+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-919347058.jpg https://infobreast.it/letteratura/trastuzumab-deruxtecan-in-her2-positive-breast-cancer-patients-with-active-brain-metastases-primary-outcome-analysis-from-the-tuxedo-1-trial/ 2022-05-23T08:54:57+00:00 https://infobreast.it/wp-content/uploads/2020/06/iStock-671767370.jpg https://infobreast.it/letteratura/interim-analysis-n150-of-the-multi-national-prospective-non-interventional-eleanor-study-observing-real-life-extended-adjuvant-treatment-with-neratinib-in-patients-with-her2-hr-early-breast-c/ 2022-05-23T08:55:30+00:00 https://infobreast.it/wp-content/uploads/2020/02/iStock-1178291704.jpg https://infobreast.it/il-punto-di-vista/carcinoma-mammario-her2-positivo-updates-dallesmo-breast-cancer-2022/ 2022-05-23T09:26:32+00:00 https://infobreast.it/wp-content/uploads/2022/05/ArpinoYT.jpg https://infobreast.it/il-centro/unita-operativa-complessa-di-oncologia-macerata/ 2022-06-13T11:10:37+00:00 https://infobreast.it/wp-content/uploads/2022/06/macerata.jpg https://infobreast.it/letteratura/translational-breast-cancer-research-consortium-trial-022-neratinib-and-trastuzumab-emtansine-for-her2-breast-cancer-brain-metastases/ 2022-12-21T12:16:41+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-179310850.jpg https://infobreast.it/letteratura/retinoic-acid-receptor-signalling-plays-a-role-in-neratinib-resistance-in-her2-breast-cancer-cell-lines/ 2022-12-21T12:42:02+00:00 https://infobreast.it/wp-content/uploads/2021/03/genomica.jpg https://infobreast.it/letteratura/neratinib-vs-trastuzumab-plus-ribociclib-in-erbb2-positive-breast-cancer-preclinical-mechanistic-efficacy-study/ 2022-12-21T13:03:56+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1145877451.jpg https://infobreast.it/letteratura/a-phase-1b-study-of-neratinib-with-thp-in-metastatic-and-locally-advanced-breast-cancer-and-phase-ii-study-of-thp-followed-by-ac-in-her2-primary-inflammatory-breast-cancer-ibc-and-neratinib-wi/ 2022-12-21T13:31:39+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-477571467.jpg https://infobreast.it/letteratura/pregnancy-outcome-and-safety-of-interrupting-therapy-for-women-with-endocrine-responsive-breast-cancer-primary-results-from-the-positive-trial/ 2022-12-21T13:32:12+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1226583757.jpg https://infobreast.it/letteratura/trastuzumab-deruxtecan-versus-trastuzumab-emtansine-in-patients-with-her2-positive-metastatic-breast-cancer-updated-results-from-destiny-breast03-a-randomised-open-label-phase-3-trial/ 2022-12-21T13:37:52+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-840201300.jpg https://infobreast.it/letteratura/efficacy-and-safety-of-the-addition-of-internal-mammary-irradiation-to-standard-adjuvant-radiation-in-early-stage-breast-cancer-a-systematic-review-and-meta-analysis/ 2022-12-21T13:47:20+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-513387572.jpg https://infobreast.it/letteratura/a-10-gene-signature-to-predict-the-prognosis-of-early-stage-triple-negative-breast-cancer/ 2022-12-21T13:54:46+00:00 https://infobreast.it/wp-content/uploads/2020/10/iStock-1036354910.jpg https://infobreast.it/il-punto-di-vista/highlights-dal-san-antonio-breast-cancer-symposium-2/ 2022-12-22T10:19:42+00:00 https://infobreast.it/wp-content/uploads/2022/12/De-laurentiis.jpg https://infobreast.it/letteratura/genomic-analysis-of-circulating-tumor-dna-from-patients-with-hr-her2-mutant-metastatic-breast-cancer-enrolled-in-summit-mechanisms-of-acquired-resistance-to-neratinib-fulvestrant-trastuzumab/ 2023-12-12T13:45:53+00:00 https://infobreast.it/wp-content/uploads/2021/03/iStock-1182847134-scaled.jpg https://infobreast.it/letteratura/interim-analysis-from-eleanor-a-multi-national-prospective-noninterventional-study-among-patients-with-her2-and-hr-early-breast-cancer-treated-with-extended-adjuvant-neratinib-in-the-clinical-rou/ 2023-12-12T13:47:15+00:00 https://infobreast.it/wp-content/uploads/2020/12/iStock-1199586270.jpg